Specifically, among patients aged 60 years and older with life-threatening COVID-19, 11.8% (95% CI: 6.5–20.3) exhibited neutralizing antibodies against IFN-α2, and 9.4% (95% CI: 4.8–17.5) had neutralizing antibodies against IFN-ω; in contrast, among patients aged younger than 60 years, none had IFN-α2 or IFN-ω neutralizing antibodies (Fig. 2). This evidence concerns the gene IFNA2 and COVID-19.